- Home
- IVVD vs XCUR Comparison
IVVD vs XCUR Comparison
Compare IVVD & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- XCUR
- Stock Information
- Founded
- IVVD 2020
- XCUR 2011
- Country
- IVVD United States
- XCUR United States
- Employees
- IVVD N/A
- XCUR N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- XCUR Biotechnology: Pharmaceutical Preparations
- Sector
- IVVD Health Care
- XCUR Health Care
- Exchange
- IVVD Nasdaq
- XCUR Nasdaq
- Market Cap
- IVVD 69.0M
- XCUR 67.8M
- IPO Year
- IVVD 2021
- XCUR N/A
- Fundamental
- Price
- IVVD $0.93
- XCUR $10.46
- Analyst Decision
- IVVD Strong Buy
- XCUR
- Analyst Count
- IVVD 3
- XCUR 0
- Target Price
- IVVD $5.85
- XCUR N/A
- AVG Volume (30 Days)
- IVVD 3.1M
- XCUR 11.4K
- Earning Date
- IVVD 05-15-2025
- XCUR 06-16-2025
- Dividend Yield
- IVVD N/A
- XCUR N/A
- EPS Growth
- IVVD N/A
- XCUR N/A
- EPS
- IVVD N/A
- XCUR N/A
- Revenue
- IVVD $36,688,000.00
- XCUR $500,000.00
- Revenue This Year
- IVVD $606.63
- XCUR N/A
- Revenue Next Year
- IVVD $83.30
- XCUR N/A
- P/E Ratio
- IVVD N/A
- XCUR N/A
- Revenue Growth
- IVVD N/A
- XCUR N/A
- 52 Week Low
- IVVD $0.35
- XCUR $1.44
- 52 Week High
- IVVD $2.74
- XCUR $36.00
- Technical
- Relative Strength Index (RSI)
- IVVD 63.94
- XCUR 48.74
- Support Level
- IVVD $0.81
- XCUR $9.01
- Resistance Level
- IVVD $1.00
- XCUR $11.00
- Average True Range (ATR)
- IVVD 0.12
- XCUR 0.43
- MACD
- IVVD 0.02
- XCUR -0.00
- Stochastic Oscillator
- IVVD 64.76
- XCUR 60.67
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.